Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy


1 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
2 Department of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
3 Department of Surgery, Yokohama City University, Yokohama, Japan

Correspondence Address:
Toru Aoyama,
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Background: The factors associated with the survival and prognosis of peritoneal cytology (CY)-positive pancreatic cancer patients who undergo curative resection followed by adjuvant chemotherapy have not been established. Patients and Methods: Both overall survival (OS) and recurrence-free survival (RFS) were examined in 23 peritoneal CY-positive pancreatic cancer patients who underwent curative resection followed by adjuvant chemotherapy between 2005 and 2015. Results: When the length of OS was evaluated using a log-rank test, significant differences were observed in the number of metastatic lymph nodes. In addition, univariate and multivariate analyses demonstrated that the number of metastatic lymph nodes was a significant independent risk factor for OS and a marginally significant risk factor for RFS. The 3-year OS rate was 20.2% in patients with ≤8 metastatic lymph nodes, and it was 0% in those with the ≥9 metastatic lymph nodes (P = 0.017). The 3-year RFS rate was 6.3% in patients with ≤8 metastatic lymph nodes, whereas it was 0% in those with ≥9 metastatic lymph nodes (P = 0.062). Conclusions: The number of metastatic lymph nodes is the most important prognostic factor for OS and RFS in peritoneal CY-positive pancreatic cancer patients who underwent curative resection followed by adjuvant chemotherapy. To improve the survival of these patients, it is necessary to establish optimal treatments.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Aoyama T
    -  Atsumi Y
    -  Kazama K
    -  Murakawa M
    -  Shiozawa M
    -  Kobayashi S
    -  Ueno M
    -  Morimoto M
    -  Yukawa N
    -  Oshima T
    -  Yoshikawa T
    -  Rino Y
    -  Masuda M
    -  Morinaga S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed135    
    PDF Downloaded8    

Recommend this journal